Home › Funds › TCV Trust & Wealth Management, Inc. › ABT

TCV Trust & Wealth Management, Inc. position in ABT

ABBOTT LABORATORIES · Health Care

TCV Trust & Wealth Management, Inc. reported holding 129,001 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$12.7M, representing 0.99% of its reported portfolio and ranking #37 among its reported holdings. TCV Trust & Wealth Management, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)129.00K sh
Reported value held$12.75M
Portfolio Weight0.99%
First reportedQ3 2023
Last changeAdd
Updated2026-10-16

Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR

How TCV Trust & Wealth Management, Inc.'s ABT position evolved

TCV Trust & Wealth Management, Inc. first disclosed a stake in ABT in Q3 2023 at 119,355 shares (US$11.6M). The position peaked in Q2 2025 at 122,074 shares, worth US$16.6M. Across 13 filings, TCV Trust & Wealth Management, Inc. increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 129,001 shares valued at US$12.7M — an increase of 3,284 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 119.36K $11.56M New
Q4 2023 120.15K $13.23M Add
Q1 2024 118.01K $13.41M Reduce
Q2 2024 120.05K $12.47M Add
Q3 2024 119.40K $13.61M Reduce
Q4 2024 121.86K $13.78M Add
Q1 2025 123.53K $16.39M Add
Q2 2025 122.07K $16.60M Reduce
Q3 2025 119.12K $15.96M Reduce
Q4 2025 123.77K $15.51M Add
Q1 2026 122.52K $12.58M Reduce
Q2 2026 125.72K $11.41M Add
Q3 2026 129.00K $12.75M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has TCV Trust & Wealth Management, Inc. held ABT?

TCV Trust & Wealth Management, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is TCV Trust & Wealth Management, Inc.'s current position in ABT?

As of Q3 2026, TCV Trust & Wealth Management, Inc. holds 129.00K shares of ABT (ABBOTT LABORATORIES), valued at $12.75M, representing 0.99% of its reported portfolio and ranking #37.

Has TCV Trust & Wealth Management, Inc. been buying or selling ABT?

In the latest 13F filing (Q3 2026), TCV Trust & Wealth Management, Inc. increased its position in ABT. The position peaked in Q2 2025 at 122.07K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.